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College of Medicine, Tucson, AZ, United States

Appropriate innate immune function is essential to limit pathogenesis and
severity of severe lower respiratory infections (sLRI) during infancy, a leading
cause of hospitalization and risk factor for subsequent asthma in this age group.
Employing a systems biology approach to analysis of multi-omic proﬁles
generated from a high-risk cohort (n=50), we found that the intensity of
activation of an LPS-induced interferon gene network at birth was predictive
of sLRI risk in infancy (AUC=0.724). Connectivity patterns within this network
were stronger among susceptible individuals, and a systems biology approach
identiﬁed IRF1 as a putative master regulator of this response. These ﬁndings
were speciﬁc to the LPS-induced interferon response and were not observed
following activation of viral nucleic acid sensing pathways. Comparison of
responses at birth versus age 5 demonstrated that LPS-induced interferon
responses but not responses triggered by viral nucleic acid sensing pathways
may be subject to strong developmental regulation. These data suggest that
the risk of sLRI in early life is in part already determined at birth, and additionally
that the developmental status of LPS-induced interferon responses may be a
key determinant of susceptibility. Our ﬁndings provide a rationale for the
identiﬁcation of at-risk infants for early intervention aimed at sLRI prevention
and identiﬁes targets which may be relevant for drug development.
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predict sLRI in the ﬁrst year of life. The rationale for selecting
these pathways is that previous studies have highlighted the role
of bacteria, respiratory viral infections, and innate immune
responses to the selected TLR agonists in asthma risk (7, 9, 15,
30–33).

Introduction
Severe lower respiratory tract infections (sLRIs) are a leading
cause of emergency room presentations by infants and children
(1, 2), and are a major risk factor for the development of asthma
and wheeze (3–6). Rhinovirus (RV) and Respiratory Syncytial
Virus (RSV) are the most important triggers of early life
respiratory infections and asthma development (7–9). Several
studies have found that associations between sLRI and asthma
are strongest in children with RV-related wheezing and early
aeroallergen sensitization (5, 6, 10, 11), although a causal
relationship remains to be established (7). However, RV can
routinely be detected in asthmatic children in the absence of
asthmatic symptoms, suggesting that RV may be necessary but
not sufﬁcient to drive the pathogenesis of asthma (12). In this
regard it has been demonstrated that bacterial pathogens,
including Moraxella, Streptococcus, and Haemophilus species,
are important triggers of wheezy episodes in young children (13,
14), and may also contribute towards asthma inception (15, 16).
Furthermore, the presence of pathogenic bacteria in the
nasopharynx during acute respiratory viral infections may
increase the likelihood of infection spread to the lower
airways, amplifying ensuing inﬂammatory symptoms and
increasing risk of subsequent asthma development (17, 18),
although much remains unknown regarding virus-bacteria
interactions in the airways and asthma development (19, 20).
Conversely, exposure to microbes and their products during
early childhood has also been shown to protect against asthma,
perhaps most elegantly illustrated through the “farm effect” (21,
22). The underlying immunological mechanisms that determine
why some individuals are more susceptible to sLRIs in early life,
and subsequent asthma, are not well understood. Innate
immune function in the immediate postnatal period, which
experiences drastic developmental changes (8, 23–25), provides
a logical link between early life microbial exposure and infection
susceptibility. This has prompted investigation of molecular
events downstream of pathogen recognition receptor (PRR)
activation, such as Toll-like receptors (TLRs), in blood
collected at birth and in early life (26–31). For example,
reduced type 1/3 interferon response capacity following
stimulation with Polyinosinic-polycytidylic acid (Poly(I:C)) – a
potent activator of TLR3 – in cord blood cells is associated with
increased risk for febrile LRIs and early childhood wheeze (31).
Moreover, enhanced production of the proinﬂammatory
cytokine IL-1b following bacterial lipopolysaccharide (LPS)
activation of cord blood was observed in individuals at risk of
childhood-onset asthma, in association with increased SMAD3
methylation and maternal asthma status (30). These examples
reveal that aspects of innate immunity which may confer risk for
sLRIs and subsequent asthma are already detectable at birth. The
aim of the present study was to determine if innate immune
response proﬁles induced by bacterial LPS or viral nucleic acid
sensing pathways (Poly(I:C) and Imiquimod) at birth could
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Materials and methods
Study population
Subjects were a subset of 50 individuals from the Childhood
Asthma Study, a 10 year prospective birth cohort enrolled
prenatally for high risk of asthma development, as described
previously (5, 31, 34–36). Of the 60 subjects with at least one
CBMC aliquot remaining from the cohort, nine were excluded
due to insufﬁcient information (withdrawn before the 1 year
follow-up) and a further subject was excluded for insufﬁcient
sample volume. Acute respiratory infections were considered
sLRIs if wheeze and/or fever was present in addition to chest
rattle, as this deﬁnition has previously been linked to persistent
wheeze and asthma in this cohort (5, 35) (Supplementary
Methods). Respiratory viral infection histories were
determined from detailed assessment and nasopharyngeal
aspirates (RT-PCR) collected during home visits within 48
hours of symptom development (5, 34). Ethics was approved
by The University of Western Australia (reference RA/4/1/
7560), and fully informed parental consent was obtained for
all subjects.

Immunophenotyping
Approximately 1x106 CBMCs from each sample were
immunophenotyped with a panel of 11 monoclonal antibodies
to measure CD3, CD4, CD11c, CD14, CD19, CD25, CD123,
CD127, FcϵRIa, FoxP3, and HLA-DR. Individual cells were
acquired using the LSRFortessa platform with FACSDiva
software (BD Biosciences) following quality control measures.
FlowJo (v10.5) software and R were used for pre-processing and
analysis (Supplementary Methods).

In vitro cell culture
Samples were assigned randomized blocks and cultured
sequentially by the same personnel using consistent reagent/
stimuli stocks. Cord blood erythrocytes were
immunomagnetically depleted (EasySep kit, StemCell, Cat no.
18170) and each sample was cultured in RPMI 1640 (Gibco, Cat
No. 11875119) supplemented with 5% AB serum (SigmaAldrich, Cat. No. H3667) for 18 hours (37°C, 5% CO2) with
1ng/ml LPS (Enzo Biochem, Cat No. ALX-581-007-L001;
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derived from E. coli, serotype R515), 5ml/ml Imiquimod (In vivo
Gen, Cat. Code: tlrl-imq) or 50ml/ml Poly(I:C) (In vivo Gen,
Cat. Code: tlrl-pic), alongside matched unstimulated controls.
Poly(I:C), bacterial LPS, and Imiquimod were selected
as they are activators of TLRs 3, 4, and 7, respectively,
thereby triggering innate immune responses to LPS and viral
nucleic acid sensing pathways. However, it is noteworthy
that Poly(I:C), a synthetic analogue of double-stranded RNA,
can also activate the viral-related PRRs RIG-I and MDA5 (37).
Aliquots of culture supernatant were immediately snap frozen
in liquid nitrogen for metabolomic proﬁling or stored at -20°C
for cytokine quantiﬁcation. Cell pellets were stored in TRIzol
reagent (Invitrogen, Cat No. 15596026) at -20°C for
RNA extraction.

reference proﬁles curated from the Human Cell Atlas (44).
Gene expression data was partitioned into response contextspeciﬁc modules with WGCNA (45). Modules were annotated
by employing a consensus approach derived from Gene
Ontology (GOenrichmentAnalysis), ReactomePA (46), and
clusterProﬁler (47) R packages, and InnateDB (42).
Additionally, we employed the blood transcriptional module
repertoire from BloodGen3Module to conﬁrm that the principal
modules of interest related to innate immune function we
identiﬁed following WGCNA analysis (interferon and
proinﬂammatory modules) were captured with an independent
method (48). Separate response networks were created for each
condition and included matched unstimulated controls, as
detailed in the Supplementary Methods.

Data generation

Master regulator analysis

Detailed information on sample and data processing and
quality control are available in the Supplementary Methods.
RNA-Seq: RNA was puriﬁed with RNeasy MinElute Kits
(Qiagen, Cat No. 74204) and libraries were prepared with
NEBNext Ultra II Kits (NE BioLabs) for sequencing on the
NovaSeq 6000 (Illumina) platform. Standard methods were
applied for pre-processing, alignment (GRCh38), and
transcript quantiﬁcation. RNA-Seq data is available from the
NCBI Gene Expression Omnibus repository (38) (accession
number GSE184383).
Cytokines: The concentrations of 48 cytokines (Bio-plex Pro,
BioRad, Cat. No: 12007283) were simultaneously quantiﬁed with
the Luminex 200 system (Luminex). Nine cytokines were outside
the limit of detection in >20% of stimulated samples and were
removed. Raw and processed data are provided in Data S1.
Metabolites: Untargeted metabolomic data was generated
with liquid chromatography (HILIC and C18 modes) separation
coupled to a Q Exactive Orbitrap mass spectrometer (Thermo
Fisher Scientiﬁc) in electrospray positive ionisation mode (LCMS/MS). QC samples were interspersed throughout the run
order to assess and correct variability. Metabolites were ﬁltered
according to stringent statistical and annotation thresholds (39).
Raw and processed data are provided in Data S2.

To identify transcription factors that act as master regulators
of gene expression proﬁles, a gene regulator network was reverse
engineered with ARACNe (49) and transcription factor activity
was inferred with VIPER (50) (detailed in Supplementary
Methods). Signiﬁcant TFs (p<0.05) were considered drivers of
the responses if they had known binding motifs in the region of
regulon target genes (500bp upstream and 100bp downstream)
determined by RcisTarget (51). Normalised expression scores
(NES) outputted from VIPER were retained for
downstream analysis.

Machine learning
Gene expression data was randomly assigned into training
and validation sets and ﬁltered to only the respective module
genes for each analysis. The random assignment was 50%
training/50% validation. The RandomForest R package was
used for random forest model construction, and the number
of decision trees (ntree) and candidate variables (mtry) were
optimized according to the out-of-bag error rate (Supplementary
Methods). Model construction and classiﬁcation was repeated
thousands of times after randomly re-assigning samples into
train/validation groups (retaining the original optimized
parameters) and this was repeated with 60/40 and 70/30 splits
(Supplementary Methods). This step was included to ensure the
results were robust with respect to the randomized train/test
group assignment. The same random assignment with respect to
individual subjects was applied for LPS/CTRL, Poly(I:C)/CTRL,
and Imiquimod/CTRL models. For random forest models used
to predict infection status in independent cohorts of infant/
childhood infection, CAS cohort data was ﬁltered to respective
module genes and used as the training set, and the external gene
expression data was used for validation (ﬁltered to identical
input genes).

Transcriptomic analysis
Differentially expressed genes (DEG) were identiﬁed [EdgeR
(40)] using an absolute log2 fold change >1.5 and an adjusted P
value < 0.01 (Benjamini-Hochberg adjusted False Discovery
Rate). Moderated t-statistics were calculated with limma/voom
(41). Pathways analysis of upregulated/downregulated genes was
performed with InnateDB (42). Cellular composition was
estimat ed from post -cultur e gene e xpression with
CIBERSORTx (43) with single cell RNA-seq cord blood
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TABLE 1 Characteristics and representativeness of the study subset.

CAS subset (n=50)

Total CAS cohort (n=263)

OR (95% CI)

Sex (female)

24/50 (48%)

115/251 (45.82%)

0.92 (0.48-1.77)

0.88

Gestation (weeks; mean [range])

39.14 [36-41]

39.03 [34-41]

NA

0.89

Birth weight (grams; mean [range])

P value

3496.52 [2755-4415]

3406.17 [2085-5110]

NA

0.27

SPT+ at 0.5, 2, or 5 years

24/50 (48%)

118/198 (59.6%)

1.59 (0.82-3.13)

0.15

URI in ﬁrst year

47/50 (94%)

215/235 (91.49%)

0.69 (0.13-2.46)

0.78

LRI in ﬁrst year

39/50 (78%)

160/235 (68.08%)

0.6 (0.26-1.28)

0.18

sLRI in ﬁrst year

23/50 (46%)

101/235 (42.98%)

0.88 (0.46-1.72)

0.75

Current wheeze at 5 years

14/43 (32.56%)

56/198 (28.28%)

0.82 (0.38-1.8)

0.58

Asthma at 5 years

9/34 (26.47%)

37/198 (18.69%)

0.64 (0.26-1.69)

0.35

CAS, Childhood Asthma Study; OR, Odds Ratio; CI, Conﬁdence Interval; URI, Upper respiratory Infection (viral); (s)LRI, (severe) Lower respiratory Infection (viral); SPT, Skin Prick Test.
SPT positivity was determined from a panel of seven common allergens (house dust mite, cat dander, ryegrass, Alternaria, Aspergillus, cow’s milk, and egg white), along with positive
(Histamine) and negative (saline) controls at 6 months, 2 years, and 5 years (Supplementary Methods). sLRIy1 represents the primary outcome (sLRI incidence in the ﬁrst year of life). For
categorical variables, odds ratios, 95% CIs and accompanying P values were determined by Fishers Exact test. For continuous variables, P values were determined by Mann-Whitney U test.
Variation in participant number relates to data availability (see Methods).

Multi-omic data integration

Baseline ﬂow cytometry

A DIABLO (52) model was constructed for supervised
multi-omic data integration, which generalizes Partial Least
Squares analysis to maximize co-expression between matched
datasets. All datasets (except immunophenotyping) for LPSstimulated CBMC samples were baseline adjusted prior to
analysis, and gene expression data was ﬁltered to signiﬁcantly
variable genes (n=6344) to reduce noise. The number of
components and feature selection parameters were tuned with
5x cross-validation (Supplementary Methods).

We applied an 11-colour ﬂow cytometry panel to baseline
cord blood mononuclear cell (CBMC) samples to assess cellular
composition. Lymphocytes (T and B cells) composed the
majority of cell types identiﬁed among CBMC (Figures 1B and
S1B). CD14+ monocytes and conventional dendritic cells (cDC)
were identiﬁed among the myeloid compartment, and smaller
proportions of plasmacytoid DCs (pDC) and basophils were also
identiﬁed. The was no difference in baseline cellular composition
with respect to sLRI in the ﬁrst year of life (Figure S1C).

Results

Multi-omic proﬁling of innate immune
responses in CBMC

Study population
CBMC from all 50 subjects were cultured for 18 hours with
LPS, or Imiquimod, or Poly(I:C) to trigger innate immune
responses, along with unstimulated controls. This timepoint
was selected to capture signalling cascades downstream of the
immediate and secondary response programs (54–56). Gene
expression was proﬁled from cell pellets (RNA-Seq) and
supernatants were used to proﬁle cytokines (multiplex assay)
and metabolites (LC-MS/MS). Matching PBMC samples
collected at age 5 were available for a subset of the subjects
(n = 27), and these were cultured in parallel under the same
conditions. Following data pre-processing and ﬁltering, 17,363
transcripts, 39 cytokines, and 47 metabolites were available for
analysis (see Methods). We applied unsupervised Principal
Component Analysis (PCA; transcripts, cytokines) and
supervised Canonical Variate Analysis (CVA; metabolites)
dimensionality reduction for exploratory data analysis. The
samples from each biological layer clustered by stimuli as
expected (Figure 1C). For transcripts and cytokines, the ﬁrst
two principal components captured interferon (IFN) and

The study population consisted of a subset of 50 children
within the Childhood Asthma Study (CAS) cohort (5, 34–36,
53). 23 subjects (46%) experienced at least one wheezy and/or
febrile sLRI in their ﬁrst year (infancy) and this was the primary
outcome of interest (Table 1). These individuals typically
experienced 1 or 2 sLRIs in the ﬁrst year of life, and a similar
number recorded both wheezy and febrile (8/23, 34.8%), wheezy
only (7/23, 30.4%), and febrile only (8/23, 34.8%) sLRIs (Table
S1 and Figure S1A). No difference was observed with respect to
sex, gestational weeks, birth weight, skin prick test positivity to
common aeroallergens, and URIs in infancy for the primary
outcome (Table S1). Overall, this subset was found to be
representative of the total CAS cohort (n=263) with respect to
key clinical characteristics (Table 1). RV was the most frequent
viral agent identiﬁed from the ﬁrst year of life in this subset
(present in 56.9% of infectious nasopharyngeal samples)
followed by RSV (13.125%), and this was representative of the
total cohort (Figures 1, S1).
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B

C

D

FIGURE 1

Respiratory virus prevalence, baseline CBMC cell proportions, multi-omic data set overview. (A) Bar plot of viral agents detected from infectious
NPAs taken during year one (proportion of total virus+ NPAs). Bars denote study subset (n=50), grey ﬁll represents individuals who recorded an sLRI
in year 1 from the total cohort (n=234). (B) Immunophenotyping of baseline CBMC samples. Y-axis shows cell type as a proportion of identiﬁed
cells. Scatterplots shows median and 95% CI. (C) Multi-level dimensionality reduction for gene expression (PCA), cytokine (PCA), and metabolite
(cross validated CVA) datasets. Axes show coordinates of the ﬁrst (x-axis) and second (y-axis) components/variates. (D) Horizontal bar plots showing
top contributing features for the ﬁrst (i-iii) and second (iv-vi) principal components or canonical variates for the corresponding plots in (C), above.
X-axis shows absolute contribution (%)/loading; red/blue indicates positive/negative relative contribution.
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proinﬂammatory features (e.g., CXCL10/IP-10, IL-1b, IL-6)
(Figure 1D). Poly(I:C)-stimulated cord blood sample clustering
by metabolites was driven by lysine on the ﬁrst canonical variate,
and other amino acids (e.g., glutamine, histidine) were identiﬁed
for the second and third canonical variates (Figures 1C, D,
S1D,E).

Identiﬁcation of co-expression networks
underlying the innate immune responses
at birth
Genes do not function in isolation, they work together in
networks (57), and for this reason gene expression data is not only
informative for differences in expression magnitude (e.g. fold
changes) but also in network structure (e.g. connectivity). We
employed weighted gene co-expression network analysis
(WGCNA) to elucidate the global connectivity structure and
functional organisation of gene expression patterns observed
from our CBMC samples. This analysis identiﬁed 11, 11, and 8
co-expression modules for the LPS, Imiquimod and Poly(I:C)
responses, respectively (Figures 2C–E, S3A,B). All responses
exhibited upregulation of IFN and proinﬂammatory modules,
and as we had already identiﬁed these as integral components of
the cord blood innate responses with dimensionality reduction and
differential expression analysis, they were therefore carried forward
for downstream analysis (Figures 2C–E, S3C–E). The LPS response
had the smallest IFN module (180 genes) compared to Imiquimod
(1114 genes) and Poly(I:C) (2201 genes) and the inverse was true of
the proinﬂammatory modules (LPS, 2297 genes; Imiquimod, 924
genes; Poly(I:C), 646 genes) (Figure 2F). Notably, there was
substantial overlap between IFN and proinﬂammatory module
genes of different stimuli, particularly between the Poly(I:C) IFN
and LPS proinﬂammatory modules (n=385 genes) (Figure S3F).
We next compared gene network patterns between the respective
responses. First, we calculated module preservation statistics, and
the results showed that the LPS-induced IFN module was highly
preserved within the IFN modules of the imiquimod and Poly(I:C)
responses but not vice versa (Figure S3G). The IFN modules
associated with the imiquimod and Poly(I:C) responses were
preserved within one another and the proinﬂammatory modules
were preserved between all responses (Figure S3G). Second, we
calculated ranked gene expression and ranked connectivity to
compare modules. A prominent disparity was observed between
expression magnitude (r = 0.88 & 0.82) and intra-module
connectivity (r = 0.57 & 0.59) between the cord blood LPSinduced IFN module genes and the same genes following
Imiquimod and Poly(I:C) stimulation, respectively (Figure 2G).
To examine connectivity within modules, we plotted the
connectivity density across all genes in each module and also
identiﬁed the top 20 most connected genes (Figures 3A, B). The
connectivity of the LPS-induced IFN module was characterised by a
normal distribution, whereas the viral stimuli produced left-skewed
distributions (Figure 3A). Key IFN signalling genes (e.g. IRF1,
STAT1) were present among the most connected genes within the
LPS-induced IFN module, however the strength of the most
connected genes was reduced compared to the IFN modules of
the viral stimuli (Figure 3B). The LPS-induced proinﬂammatory
module displayed greater connectivity compared to the
imiquimod- or Poly(I:C)-induced proinﬂammatory modules

IFN and proinﬂammatory gene
expression programs are upregulated in
CBMC responses
We focused on the transcriptomics data to further investigate
cord blood responses to LPS, Poly(I:C), and Imiquimod treatment
as these data provide genome-wide coverage. Employing
differential expression analysis, we identiﬁed 641 differently
expressed genes (DEGs) for the cord blood LPS response (Log2fold change > 1, FDR adjusted-P value < 0.01), and greater than
1000 DEGs for the imiquimod and Poly(I:C) responses
(Figure 2A). Pathways analysis [InnateDB (42)] identiﬁed an
enrichment of cytokine and chemokine signalling pathways
from upregulated genes in all responses, and IFN signalling
pathways were prominent for imiquimod and Poly(I:C) CBMC
responses (Figures 2B, S1F). Notably, the viral-related stimuli
triggered a common set of 429 upregulated genes and this
constituted a core antiviral response shared between Poly(I:C)
and Imiquimod responses (Figure S1G). In addition, we identiﬁed
462 and 243 genes that were speciﬁcally upregulated in response
to Poly(I:C) and Imiquimod respectively, demonstrating unique
signalling pathways downstream of their receptors (Figure S1G).
We next employed CIBERSORTx to estimate the post-culture
cellular composition from the RNA-Seq data (43). Prominent cell
types included monocytes, B cells, and CD4+ T cells (Figures S2A,
B). The erythrocyte proportion was negligible as a result of
immunomagnetic depletion (see Methods). Cell composition
changes were identiﬁed between stimuli and age, but not
sequence order or sex (Figures S2C,D). There was also no
difference in the estimated cellular composition between
individuals who were resistant or susceptible to sLRI in infancy,
aligning with the baseline ﬂow cytometry ﬁndings (Figures S1C,
S2D). We also investigated variations in innate immune gene
expression in the matching samples collected at birth versus age 5
(n=27 per age/stimuli) (Figures S2E, F). Interestingly, the LPS
response at 5 years was characterised by upregulation of IFNrelated genes, including IRF1, STAT1, and IFIT1-3, compared to
birth. In contrast, IFN-related pathways were not prominent from
differentially expressed genes between birth and age 5 following
imiquimod or Poly(I:C) stimulation (Figures S2E, F). Finally, no
genes were signiﬁcantly different between individuals resistant and
susceptible to sLRIs in infancy for any condition from this analysis
(data not shown), suggesting that sLRI risk is not conferred by
individual gene expression magnitude alone.
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FIGURE 2

IFN and proinﬂammatory gene expression following TLRs 3/4/7 activation in CBMC. (A) Volcano plot showing signiﬁcantly upregulated (red) and
downregulated (blue) genes compared to matched unstimulated samples for the LPS (i), Imiquimod (ii), and Poly(I:C) (iii) responses, respectively.
Plots show the Log2 fold-change (x-axis) and FDR-adjusted p value (-Log10 transformed). Blue and red dashed lines indicate a Log2FC of -1 and 1,
respectively; black dashed line denotes a -Log10 FDR-adjusted p value of 2. (B) Top 10 overrepresented pathways from signiﬁcantly upregulated
genes of the CBMC LPS (i), Imiquimod (ii), and Poly(I:C) (iii) responses. X-axis shows the FDR corrected p value (-Log10 transformed); black dashed
line indicated corrected p ≈ 0.05. (C–E) Modules identiﬁed from network analysis (WGCNA) of the LPS, Imiquimod, and Poly(I:C) responses,
respectively. Modules are plotted by moderated t-statistics (y-axis) and show the median, 25th and 75th quartiles ±1.5xIQR and outliers. Modules with
medians above the red line (moderated t-statistic = 2) are considered signiﬁcantly upregulated and those below the blue line (-2) are considered
signiﬁcantly downregulated. (F) Bar plot of the number of genes in the interferon and proinﬂammatory modules for the respective responses. (G)
Heatmap showing Spearman’s correlation values of ranked expression and ranked connectivity between CBMC response module genes. Expression
of member genes from the IFN and proinﬂammatory modules of each response were correlated against the expression of the same genes from the
other responses. The p value associated with all correlations was < 0.01.
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FIGURE 3

Network connectivity and master regulator analysis of IFN responses at birth and age 5 years identify IRF1 as a key driver. (A) Density plot of the
LPS (i), Imiquimod (ii), and Poly(I:C) (iii) CBMC response IFN module connectivity, respectively. Dashed line denotes median. Lilliefors p value >
0.05 indicates normal distribution. (B) Network wiring diagrams of the top 20 most connected genes for the LPS (i), Imiquimod (ii), and Poly(I:C)
(iii) CBMC IFN modules, respectively. Node size represents number of connections (degree) among the total network and edge width indicates
strength of correlation (red edges > 0.8). (C) Top 10 master regulators for the respective CBMC IFN modules. Bar plots show normalized
enrichment score (NES) for transcription factors which are signiﬁcantly activated (NES>2, red line) or inactive/inhibited (NES<-2, blue line). Grey
shading indicates an adjusted P value < 0.05. (D) Network wiring diagrams of the most connected CBMC LPS-induced IFN module genes from
matched CBMC (i) and 5 year PBMC (ii) samples. Network characteristics are the same as above (B). (E) Network connectivity density plot for
the interferon module gene connectivity of the matched CBMC (blue) and 5 year PBMC (magenta) responses to LPS (i), Imiquimod (ii), and Poly
(I:C) (iii) stimulation. (F) Top drivers of the LPS-induced interferon module genes identiﬁed for matched CBMC (i) and 5 year PBMC (ii, 9 drivers
were signiﬁcant at P <0.05 samples. Bar plot characteristics are the same as above (C).
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the ROC curve = 0.724) (Figure 4A). Whilst the accuracy of this
model may appear modest, it is known that risk biomarkers in
general possess poor accuracy to predict subsequent disease over a
speciﬁc time interval because the at-risk population will almost
always be heterogeneous with respect to the disease outcome (58).
In contrast, classiﬁers built from the Imiquimod- or Poly(I:C)induced IFN module genes were not predictive of sLRIs in the ﬁrst
year of life (Figure 4A). To test whether this ﬁnding was
reproducible given the relatively small sample numbers available
as input, we repeated the analysis by randomly re-sampling
subject membership in the training/validation sets (retaining the
initial optimization parameters), and again found that only the
LPS-induced IFN module genes could predict sLRIs in infancy
better than chance on average (Figures 4B, S6A–C). Furthermore,
we observed markedly different connectivity patterns for the LPSinduced IFN modules when stratiﬁed by individuals who did and
did not experience and sLRI in the ﬁrst year of life (Figures 4C, D,
S6D), and this was not evident from the imiquimod- or Poly(I:C)induced IFN modules (Figures 4C, S6E, F). Speciﬁcally,
susceptible individuals had stronger gene network patterns for
the LPS-induced IFN module, although the putative drivers of the
response were comparable (IRF1, STAT3, BATF) (Figures 4D, E).
Restricting the Imiquimod and Poly(I:C) IFN responses to only
those genes of the LPS-induced IFN module did not exhibit
noticeable differences in connectivity density patterns in relation
to sLRI susceptibility in infancy (Figures S6E(iii),F(iii)). Whist the
connectivity density plot of the LPS-induced IFN module of
CBMCs of susceptible individuals (Figure 4C) resembled the
overall connectivity density of the 5 year PBMC connectivity
(n=27) (Figure 3E), the intra-module connectivity was
signiﬁcantly different (Figures S6G, H), suggesting the similarity
may emerge from different processes. However, it should be noted
that among the subjects which had a PBMC sample available at 5
years (n=27), the proportion of individuals who experienced an
sLRI in infancy (29.63%) differed to that of the total subset (n=50,
46% sLRI positive in infancy). We also calculated module
eigengenes to summarise overall module expression and
compared this with clinical traits. The CBMC LPS-induced IFN
module eigengene stratiﬁed individuals susceptible to sLRIs in the
ﬁrst year of life (p=0.016), as well as those with asthma (p=0.015)
and current wheeze (p=0.02) at 5 years of age (Figures 4F, S7A,B).
This result was only signiﬁcant for the LPS response, was speciﬁc
for the IFN module, and was only observed for comparisons of
severe LRIs (Figures 4G, S7C–E).

(Figure S4A). Genes encoding innate immune/proinﬂammatory
cytokines (e.g. IL1A/B, CXCL2/3/8) were among to most connected
genes in the proinﬂammatory modules of all responses at birth
(Figure S4A). In summary, although viral nucleic acid and bacterial
related stimuli activated overlapping sets of proinﬂammatory and
IFN response genes, the underlying network structure was
markedly different.

Identiﬁcation of master regulators of the
innate immune responses at birth
and age 5
We employed VIPER (50) analysis to identify master
regulators which are predicted to drive module connectivity
patterns. This approach revealed that the LPS-induced IFN
module was putatively driven by BATF, STAT3 and IRF1
transcription factors (TFs) at birth, whereas the Imiquimodand Poly(I:C)-induced IFN module top drivers included
multiple STAT (e.g. STAT2) and IRF (e.g. IRF7) TFs
(Figure 3C). The proinﬂammatory modules for all three
responses were enriched for CEBPB, AP-1 (e.g. JUN, FOSL1/2)
and NF-kB (e.g. NF-kB, RELB) (Figure S4A). Importantly, we
repeated our analyses with input genes restricted to only those
preserved from the LPS responses IFN (169/180, 93.89%) and
proinﬂammatory (443/2297, 19.29%) modules and the result was
unchanged (Figures S4B, C). Finally, we compared gene network
patterns between CMBC and matched PBMCs samples (n=27)
collected at 5 years. The connectivity of the genes of the LPSinduced IFN module was markedly higher at 5 years compared to
birth among matched samples, suggesting that the wiring of this
module is subject to developmental regulation (Figures 3D, E).
Additionally, IRF1 enrichment was only identiﬁed from cord
blood (Figure 3F). In contrast, the IFN responses provoked by
imiquimod and Poly(I:C) stimulation displayed comparatively
similar connectivity patterns between birth and age 5 years and,
supporting this, the putative drivers were also comparable
between birth and 5 years (e.g. STAT2, IRF7) (Figures 3E, S5A).
Imiquimod and poly(I:C) proinﬂammatory modules were
characterised by reduced intra-module connectivity in blood
collected at 5 years compared to birth (Figures S5B, C).

Innate immune responses at birth are
predictive of sLRI in the ﬁrst year of life

IFN responses induced in CBMCs by TLR
ligands in vitro are representative of IFN
responses during natural infections

To determine whether innate immune responses at birth
could predict the development of sLRIs in the ﬁrst year of life,
we randomly assigned the data set into training (50%, n=25) and
validation sets (50%, n=25) and trained a random forest classiﬁer
on the CBMC IFN modules. The classiﬁer trained on the LPSinduced IFN module genes could predict sLRIs in the ﬁrst year of
life with an accuracy of 72% in the validation data set (Area under
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FIGURE 4

IFN genes activated following LPS stimulation at birth predict sLRI susceptibility in the ﬁrst year of life. (A) Random forest (RF) classiﬁers were
trained on the respective IFN module genes from half the study subjects and validated on the remaining subjects (50/50). RF models were
optimised with respect to number of genes sampled at each split and number of trees grown. Plot depicts the area under the Receiver Operator
Characteristic curve (AUC-ROC) deﬁned by the rate of false (x-axis, 1-speciﬁcity) and true (y-axis, sensitivity) positives. (B) RF model predictions
were repeated by re-sampling the training/validation set (50/50 random assignment) 2,000 times. Plot show the AUC-ROC for each re-sample,
with median (solid lines) and 95% CIs (dashed lines). (C) Network connectivity density plot of IFN module gene networks stratiﬁed by individuals
who did (orange) and did not (grey) record an sLRI in the ﬁrst year of life. (D) Network wiring diagram of the most connected genes of the
CBMC LPS-induced IFN module gene from individuals resistant (I, n=27) and susceptible (II n=23) to sLRIs in infancy. Node and edge
characteristics are the same as Figure 3B. (E) Top 10 master regulators identiﬁed for the CBMC LPS-induced IFN response module for resistant
(i) and susceptible (ii) subjects. Bar plot characteristics are the same Figure 3C. (F) Box-and-whisker plot of the CBMC LPS-induced IFN module
eigengene, grouped by susceptible (orange) and resistant (grey) individuals. Boxes show median, 25th and 75th quartiles and whiskers are
determined by the Tukey method; P value determined by Mann-Whitney U test. (G) Plot of IFN module eigengenes for CBMC responses
grouped by individuals who were resistant (-) and susceptible (+) to LRIs and sLRIs in infancy. P values determined by Mann-Whitney U test and
signiﬁcant result reﬂects (F). Plot shows median (symbol) and 95% CI (bars).
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this analysis, input genes were selected as those which were
signiﬁcantly variable between LPS-stimulated and unstimulated
CBMC samples and were not selectively enriched for IFNrelated transcripts. The data reinforced that LPS-induced IFNsignalling transcripts (IRF9, STAT1, GBP2/4) and IRF1 activity
were key determinants of risk for sLRI in the ﬁrst year of life, in
combination with lymphocyte and monocyte proportions,
immune regulators (e.g. RFX5, NFIX), amino acids, and
proinﬂammatory cytokines/chemokines (IL-1b, MIP-1a, MIF)
(Figure 5D). As we separately identiﬁed LPS-induced IRF1
activity from network, master regulator, and integrative
analyses, we further investigated IRF1 gene expression
correlations. IRF1 gene expression at birth positively correlated
with selective STAT and IRF family transcription factor genes
(e.g. STAT1, IRF7/9), proinﬂammatory mediators (e.g. IL-1b, IL6, CCL3/MIP-1a), and viral-related receptor genes (e.g. ICAM1,
IFIH1) (Figure 6A). Additionally, CBMC STAT1 and IFIH1 gene
expression was higher in response to LPS among individuals
who were susceptible to sLRIs in infancy, and IFIH1 expression
correlated with IRF1 and STAT1 expression (Figures 6B, C).

IFN responses to childhood infections in vivo. To address this issue,
we trained RF classiﬁers on our CBMC-derived IFN module genes
and used them to classify samples from publicly available data sets
from the Gene Expression Omnibus. Gene expression data from
external cohorts was ﬁltered to only those genes present in the
corresponding IFN modules for each analysis. The ﬁrst data set
comprised whole blood gene expression proﬁles from children
(<17yrs) with febrile illnesses requiring hospitalization with
conﬁrmed bacterial (n = 52) or viral (n = 92) infections versus
healthy controls (n = 52) [GSE72809 (59)]. We found that RF
classiﬁers trained on LPS- and Imiquimod/Poly(I:C)-induced IFN
module genes accurately predicted children with bacterial (AUC =
0.889) and viral (AUC = 0.874/0.838) infections, respectively
(Figures 5A, S7F). The second data set consisted of PBMC
samples from infants (<18mo, n=30) and young children (18mo5yrs, n = 32) who were hospitalized with acute viral bronchiolitis
[GSE113211 (60)]. Classiﬁers built on unstimulated and either
Imiquimod- (AUC=0.8) or Poly(I:C)- (AUC=0.877) induced IFN
genes could accurately stratify samples collected during acute illness
compared to matched post-convalescent samples (symptom-free,
8.8 ± 2.5 weeks post-infection), independent of age (Figures 5B,
S7G). The models performed well for infants (AUC = 0.922, Poly(I:
C); AUC = 0.827, Imiquimod) and children (AUC = 0.789, Poly(I:
C); AUC = 0.842, Imiquimod) separately (Figure S7G). The third
data set consisted of nasal-derived gene expression proﬁles from
study visits of asthmatic children (6-17yrs) with viral-related or
non-viral “cold”-like illness (1-6 days post-onset), some of which
later experienced exacerbations (n=83, 58 were viral-positive)
[GSE115770 (61)]. Symptomatic children with respiratory viral
infections were accurately predicted from symptomatic, yet virusnegative, children from Imiquimod (AUC=0.8) and Poly(I:C)
(AUC=0.832) deﬁned RF classiﬁers (Figures 5C, S7H).
Additionally, there was comparable accuracy classifying viruspositive and virus-negative asthmatic children who subsequently
experienced an exacerbation (within 10 days of symptom onset)
(Figure S7H). In the same study, prediction performance was less
accurate from peripheral blood-derived gene expression proﬁles
(Figure S7H). Taken together, these analyses demonstrate that
CBMC-derived IFN gene expression patterns induced with LPS,
Imiquimod, or poly(I:C) in this study are representative of
childhood IFN responses to microbial pathogens.

Discussion
Severe viral lower respiratory tract infections (sLRIs) are a
leading cause of hospitalization for infants and children and
constitute a major risk factor for subsequent asthma
development (2–6). Whilst it is increasingly recognised that
bacterial and viral pathogens may interact to drive the
pathogenesis of sLRIs, the underlying innate immune
mechanisms are not well understood. We employed a multiomic approach to systematically proﬁle innate immune
responses to bacterial (LPS) and viral nucleic acid (Poly(I:C)/
Imiquimod) related stimuli at birth to ﬁrst characterize these
responses and then investigate whether any response patterns
are associated with susceptibility to sLRI in the ﬁrst year of life.
The data showed that whilst innate immune responses to the
panel of stimuli comprised overlapping proinﬂammatory and
IFN-mediated gene expression programs, the LPS but not Poly(I:
C)/Imiquimod response proﬁles at birth were predictive of sLRI
incidence in the ﬁrst year of life. Moreover, sLRI susceptibility
was associated with the activation of a network of IFN genes, and
the connectivity patterns of this network in cord blood LPS
responses were strikingly exaggerated among infants susceptible
to sLRI. Furthermore, the connectivity pattern of these genes was
highly variable between the cord and 5 year LPS responses.
These ﬁndings were speciﬁc for the LPS-induced IFN responses
and were not observed following activation of viral nucleic acid
sensing pathways, nor from proinﬂammatory module genes of
any response tested, suggesting that the wiring of the LPS
response is speciﬁcally altered in children who are at
heightened risk for sLRI in infancy. It is noteworthy that
expression of the LPS-induced IFN module was not associated

Multi-omic integration of LPS-stimulated
CBMC data
Lastly, we employed multi-omic data integration (DIABLO
(52)) to identify correlated molecular features across biological
layers which may confer sLRI risk. Input data consisted of
CBMC baseline immune cell type proportions (n = 8),
signiﬁcantly variable mRNA transcripts (n=6344), VIPERderived regulon activity scores (n = 1224), metabolites (n =
49), and cytokine/chemokine proteins (n = 39). Importantly for
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FIGURE 5

CBMC IFN responses reﬂect natural childhood response to infection; Multi-omic integration reinforces that LPS-induced IFN signalling at birth is
a determinant of sLRI risk in infancy. (A) A random forest classiﬁer was trained on Unstimulated and LPS or Imiquimod/Poly(I:C) CBMC IFN
module gene expression data (n = 100) and used to predict children (<17yrs) hospitalized with bacterial (n = 52) and viral infections (n = 92),
respectively, from healthy controls (n = 52) from blood-derived gene expression proﬁles. Gene expression data sets were restricted to available
IFN module genes and RF models were optimised with respect to the number of genes and trees. Plot depicts the AUC-ROC deﬁned by the
rate of false (x-axis, 1-speciﬁcity) and true (y-axis, sensitivity) positives. (B) RF classiﬁers trained on Unstimulated and Imiquimod or Poly(I:C)
CBMC IFN module gene expression data (n=100) and used to predict PBMC gene expression proﬁles from infants (<18mo; n=15) and children
(18mo-5yrs; n=16) presenting to hospital with acute viral respiratory infections from proﬁles collected during convalescence. Plot depicts the
AUC-ROC. (C) RF classiﬁers trained on Unstimulated and Imiquimod or Poly(I:C) CBMC IFN module gene expression data (n=100) and used to
predict asthmatic children (6-17yrs) with cold-like symptoms who do (n=193) and do not (n=105) have detectable airway viral infection from
nasal-derived gene expression proﬁles. Plot depicts the AUC-ROC. (D) Circos plot displaying the multi-layer risk proﬁle for sLRI susceptibility in
infancy determined from multi-omic data integration, showing between block correlation from the 1st latent component; correlations stronger
that ±0.8 are shown. Peripheral lines represent the relative expression of features from individuals who were resistant (grey) or susceptible
(orange) to sLRIs in the ﬁrst year of life. Input data was adjusted with respect to matched unstimulated samples (except baseline
immunophenotype data).

Frontiers in Immunology

12

frontiersin.org

Read et al.

10.3389/ﬁmmu.2022.876654

A

B

C

FIGURE 6

LPS-induced IRF1 correlates with key interferon/proinﬂammatory mediators. (A) Plot of the association between LPS-induced IRF1 gene expression with
selected IFN and proinﬂammatory gene expression (left), viral-related receptor gene expression (center) and chemo/cytokine protein concentration
(right). Data was adjusted with respect to matched unstimulated samples and plots shows Spearman’s Rho value (symbol) and 95% CI (bars, 1000
bootstraps); Red and blue data points/labels denote positive and negative correlations, respectively, with a BH-adjusted p value <0.05. (B) Analysis of
selected IFN and proinﬂammatory gene expression (left), viral-related receptor gene expression (center) and chemo/cytokine protein concentration
(right) with respect to sLRI susceptibility in the ﬁrst year of life. Data was adjusted with respect to matched unstimulated samples and plots show the
Mann-Whitney U test estimates and 95% CIs for CBMC data of individuals who are susceptible compared to resistant to sLRIs in infancy. Red data
points/labels indicate increased expression with a p value < 0.05. (C) Spearman’s correlation and associated p value between IFIH1 (x-axis) and IRF1/
STAT1 (y-axis) gene expression from CBMC samples stimulated with LPS (n=50). Data was adjusted with respect to matched unstimulated samples.
Dashed blue line represents a loess ﬁt of the data.
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on the other hand diminishes the antimicrobial function of IL1b, resulting in increased airway and systemic M. tuberculosis
colonisation (74). This suggests a balance exists between IFN
and proinﬂammatory responses which impacts the clinical
outcome of bacterial infection, although it is not clear how
anti-bacterial responses may protect against or exacerbate viral
infections. IRF1 promotes the constitutive expression of
interferon-mediated antiviral programs at baseline and the
inducible expression of these programs triggered by
respiratory viral infections (75–78), and acts as a branch point
between IFN responses and induction of speciﬁc proinﬂammatory genes (79). The function of IRF1 following
bacterial infections is incompletely understood, although it
appears essential for IFN-related inﬂammasome activation
during Francisella novicida infection (75, 80) indicating a role
in IFN and proinﬂammatory responses following pathogenic
bacterial exposure. It is also notable in this context that IRF1
gene variants have been linked to childhood asthma risk and
dysregulated proinﬂammatory responses (81). We did not
observe a direct difference in IRF1 expression between
individuals who did or did not record an sLRI in the ﬁrst year
of life at the time point investigated in our study. This suggests
that the sLRI risk putatively associated with IRF1 may be
conferred by its regulatory actions rather than its gene
expression magnitude, or that IRF1 expression dysregulation
occurs earlier than was measured in this study (18hrs). It is our
interpretation of the data that IRF1 is a key driver of the LPSinduced IFN response networks associated with sLRI
susceptibility in the ﬁrst year of life.
The immune system of newborns is subject to drastic
developmental changes in the ﬁrst weeks (82) and months
(83) of life. Since our study focused on CBMC-derived innate
immune responses, we explored the extent to which CBMC
responses reﬂect immune responses to infections occurring at
later ages during childhood by applying classiﬁers trained on
gene expression data generate in this study to infectionassociated host response data derived from published cohorts.
This approach was not intended as validation of the principal
ﬁndings linking LPS-induced IFN response at birth with
subsequent sLRI risk, but rather to establish whether the IFN
response networks characterized from our in vitro experiments
in CBMCs are representative of those operating in nature. LPSinduced IFN responses from CBMCs were used to accurately
stratify children presenting to hospital with current bacterial
infections, compared to controls, from whole blood samples
(59). Likewise, Imiquimod/Poly(I:C)-induced CBMC IFN
responses accurately classiﬁed children with febrile viral
infections. Moreover, the CBMC-derived IFN responses
induced by imiquimod or Poly(I:C) could classify infants and
children with viral bronchiolitis and asthma exacerbations from
blood and airway samples compared to controls, suggesting that
these signatures are robust to some extent to variations in
cellular composition between circulating blood and airway

with mild (non-wheezy/non-febrile) lower respiratory tract
infections, highlighting a speciﬁc link to infection severity.
Master regulator analysis identiﬁed IRF1 as a key driver of
LPS-induced IFN responses at birth. By age 5, the data showed
that the activity of IRF1 may be replaced by other members of
the IRF transcription factor family, including IRF7, suggesting
that this response is subject to developmental regulation. In
contrast, IRF7 was the dominant driver of Poly(I:C)-/
Imiquimod-induced IFN response at birth and 5 years. IRF1
was also identiﬁed as a highly connected node of the LPSinduced IFN network and correlated with distinct IFN-signalling
(e.g. STAT1 but not JAK1/TYK2) and proinﬂammatory (e.g.
CXCL9/10/11, IL-1b) mediators, several of which exhibited
signiﬁcantly higher expression in infants at risk of sLRI. These
data suggest that an LPS-induced and IRF1-regulated IFN gene
network, detectable at birth, is associated with sLRI susceptibility
in infancy. Consequently, we conclude that susceptibility to sLRI
in infancy may be in part already determined at birth and this
may be exploited to identify at-risk infants for early intervention
and identify potential targets for drug development.
The contribution of bacteria and their products to the
severity of viral-related respiratory infections has been
suggested by numerous studies. For example, environmental
LPS exposure modulates the severity of RSV infections
depending on the levels of LPS exposure and TLR4 genotype
(62). Moreover, studies from our group in the same cohort have
demonstrated that sLRIs are often preceded by the transient
incursion of pathogenic bacteria in the airway microbiome (17,
18). Multiple other studies have reported that the presence of
pathogenic bacteria in the airways is associated with more severe
viral respiratory tract infections for both RSV and RV (63–66).
Additionally, bacterial colonization of the airway in neonates
with Streptococcus pneumoniae, Haemophilus inﬂuenzae, or
Moraxella catarrhalis was associated with persistent wheeze
and severe exacerbations of wheeze (15), which are generally
initiated by viral respiratory infections. Finally, Illi et al.
demonstrated that LPS responses at 12 months of age in
individuals who carry asthma-risk alleles on 17q21 are
associated with risk of wheeze (32).
The proposition that heightened LPS-induced IFN
responses/gene network connectivity patterns at birth may
confer risk of viral-related sLRI during infancy at ﬁrst sight
may appear counterintuitive given the acknowledged protective
role of IFNs in antiviral immunity (67, 68). However, hyperproduction of IFNs in the airways during viral-associated
infections, especially during infancy, are also known to
contribute to accompanying inﬂammatory symptom severity
(60, 69). Furthermore, IFN responses during bacterial
infections have pleiotropic effects which may be beneﬁcial or
detrimental, depending on the site of infection and the speciﬁc
pathogen involved (70, 71). For example, type I IFN mediated
suppression of IL-1b responses (72) on the one hand attenuates
lethal hyperinﬂammation associated with S. pyogenes (73) and
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tissue. We also found that the accuracy of the random forest
models was higher when predicting infants (<18mo) compared
to younger (18mo-5yrs) (GSE113211 (60)) or older (6-17yrs)
children (GSE115770 (61)). These data support that the IFN
gene networks identiﬁed from our in vitro investigation of cord
blood are bona ﬁde response mediators of infection in real
world contexts.
We acknowledge that our study has limitations that should
be addressed. Firstly, gene expression proﬁles were generated
from mixed cord blood cell populations and as such cannot
distinguish cell-speciﬁc information. Further investigation with
single-cell RNA sequencing may localize gene expression
programs potentially responsible for sLRI risk in individual
cells. Secondly, the study population consisted of 50 subjects
from a high-risk cohort, limiting the power to detect diseaseassociated mechanisms. Follow-up studies with samples from
large, unselected cohorts may identify more subtle mechanisms
that confer risk for sLRI. Additionally, we utilised CBMC
samples for this work, because they are readily available and
abundant at birth. However, recent advances in sample
processing methods now enable the generation of multi-omic
data from small sample volumes, enabling longitudinal
proﬁling of infants/children with natural infections (82). We
proﬁled innate immune responses at a single timepoint
(18hrs), and therefore our analyses cannot capture response
dynamics. Finally, we employed three TLR ligands to
mimic PRR activation events experienced during bacterial or
viral infections. However, we acknowledge using TLR ligands is
not equivalent to using live bacteria or virus. Notwithstanding
these limitations, the major strengths of this study lie in the
systems biology approach that provided genome-wide
investigation of the CBMC responses, and the well
characterized prospective cohort design, which allowed us to
investigate sLRI risk with the totality of viral infections
and relevant clinical outcomes recorded. In summary, our
ﬁndings demonstrate that the risk of sLRI in early life is in
part already determined at birth, and that the developmental
status of LPS-induced interferon responses may represent a key
factor which confers susceptibility. Our ﬁndings provide a
rationale for the early identiﬁcation of infants at risk for sLRI
and identiﬁes potential targets which may be relevant for
drug development.
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